Indications for implantable cardioverter defibrillators (ICDs) are expanding. Defining long-term predictors of ICD therapies might help to identify those patients who will benefit most from implantation of an ICD. The objective of this study was to examine longterm predictors of appropriate ICD therapy among patients with coronary disease at high risk of sudden cardiac death.
ARRHYTHMIA-RELATED sudden death remains a major cause of mortality among patients with coronary artery disease. Implantable cardioverter-defibrillator (ICD) therapy has become the standard of care for secondary prevention of sudden cardiac death during the last 25 years. More recently, randomized controlled trials have demonstrated a survival benefit among patients at high risk of sudden cardiac death treated with an ICD in primary prevention settings. [1] [2] [3] [4] However, ICD therapy is associated with high economic costs, potential complications, and inappropriate ICD therapy may cause patient discomfort, anxiety, and proarrhythmia. 5) Therefore, the ability to identify patients that would benefit most and least from ICD implantation, or from replacement after battery depletion, is of major importance. Randomized controlled trials provide the best evidence of the treatment effect of therapeutic interventions. However, they include highly selected patients, which may lead to overestimation of the benefit that may be achieved in clinical practice. Longitudinal studies may provide important complementary information which may help the clinician to better understand the benefits and limitations associated with specific therapies. Clinical risk factors which predicted future appropriate ICD therapies in previous studies include low left ventricular ejection fraction, higher New York Heart Association (NYHA) functional class, and not taking beta-blockers. 6) Many studies assessing risk factors for future ICD therapies provide limited follow-up and have included patients with various cardiac diseases. However, arrhythmia risk may vary according to the etiology of myocardial disease. In addition, many studies are limited to patients with a markedly reduced ejection fraction. Therefore, the purpose of this study was to evaluate the rate and predictors of appropriate ICD therapies during long-term follow-up of patients with coronary artery disease and an ejection fraction below as well as above 35%.
Methods
Patients: Patients with coronary artery disease undergoing first-time implantation of an ICD at the University Hospital Zurich were included in this observational study. All patients had either primary or secondary prevention indications according to the current AHA/ACC/NASPE guidelines at the time of implantation (Table I) . Devices were programmed individually according to arrhythmia and patient characteristics. Baseline demographical data, clinical characteristics, history, ECG, and results of coronary angiography and echocardiography were collected from all patients. Arterial hypertension was defined as blood pressure above 140/90 mmHg or any blood pressure in a patient taking antihypertensive medication. Diabetes was defined as fasting plasma glucose > 7 mmol/L, or taking antidiabetic drugs. Renal insufficiency was defined as an estimated creatinine clearance < 60 mL・min -1 ・1.73m -2 . Electrophysiologic study was performed in selected patients based on individual patient history and clinical presentation according to the guidelines. Extent of coronary artery disease was determined by coronary angiography in most patients using standard techniques and was graded as one-vessel, two-vessel, or three-vessel disease. Systolic left ventricular function was assessed by biplane calculation of the left ventricular ejection fraction at coronary angiography or by echocardiography among patients in whom coronary angiography was not performed. All patients provided written informed consent for device implantation.
The study was conducted according to the relevant federal and institutional ethics guidelines, and the registry was approved by the institutional review board. All patients provided written informed consent for inclusion of their clinical data in the research database and for use of their clinical data for research purposes. Follow-up: All patients underwent follow-up scheduled at 3 weeks and 3 months after device implantation and every 6 months thereafter. Patients were instructed to contact the clinic after an ICD discharge for an additional appointment. At each visit, patients were assessed clinically and a complete device interrogation was performed. Occurrence of an ICD shock or antitachycardia pacing was confirmed by device interrogation and analysis of the stored electrograms. All therapies were classified as appropriate or inappropriate by two independent experienced electrophysiologists. The endpoint of the study was the occurrence of any appropriate ICD delivered therapy, whether shock or antitachycardia pacing. Statistical analysis: Categorical variables are presented as counts (%) while continuous variables are presented as mean (SD) or median (interquartile range), depending on distribution of the data. Groups were compared using the chisquare test for categorical variables. The unpaired t-test was used for continuous variables, and the Mann-Whitney U test was used for variables with skewed distribution. The incidence of ICD therapy over time was analyzed for different patient groups by the Kaplan-Meier method for time to event curves and with the log-rank test for comparison. Cox regression analysis was used to identify predictors of ICD therapies. Variables that were significant (P < 0.05) in the univariate analysis were included in the multivariate model. All probability values were 2-sided, and a value of P ≤ 0.05 was considered significant. Statistical analysis was performed with SPSS software version 12.0.
Results
Patients: Two hundred and forty-five patients (91% men) with CAD underwent implantation of an ICD at the University Hospital Zurich, Switzerland. Coronary angiographic data were available from 90% of all patients. The ejection fraction ranged from 75% to 7%, with 117 patients revealing an ejection fraction ≥ 35% and 128 patients with an ejection fraction < 35%. Baseline characteristics of the patients are presented in Table II . Mean (SD) duration of follow-up was 41 (33) months, resulting in a cumulative follow-up time of 832 patient-years. Thirtyfour patients (14%) died during the study period. Devices: For arrhythmia detection, a ventricular fibrillation (VF) detection zone was programmed in all systems, a single ventricular tachycardia (VT) detection zone was programmed in 76%, and two VT detection zones were used in 18%. The mean (SD) detection threshold for VF was 203 (15) bpm, and 168 (15) bpm and 148 (17) bpm for VT. 
PREDICTORS OF ICD THERAPY IN CORONARY DISEASE
Therapies: Appropriate ICD therapies were delivered in 115 (47%) of the patients. Of those, 52 (45%) experienced antitachycardia pacing but no shocks, and 45 (39%) had shocks only. In 18 (16%) patients, shocks were delivered after unsuccessful antitachycardia pacing. In 15 patients (13%) at least one episode of an inappropriate therapy occurred before the first adequate therapy. A total of 30 patients (12%) experienced at least one episode of an inadequate therapy. One year after implantation of the ICD, 86 (35%) of the patients had experienced at least one appropriate device therapy. Eighty-four (34%) patients received a device change during the study period. Of those, 5 patients (6%) experienced their first adequate device therapy thereafter. The longest interval to the first appropriate ICD therapy was 12 years. Predictors of appropriate ICD therapy: Cox regression analysis was performed to obtain unadjusted hazard ratios for clinical variables to identify predictors of appropriate device therapy (Table III) . Age, renal insufficiency, left ventricular ejection fraction below 35%, and a time interval of more than 6 months between myocardial infarction and implantation of the ICD were significantly associated with higher risk of appropriate ICD therapy. After including these variables in a multivariate model, age (adjusted hazard ratio 1.36 per 10 years [95% CI, 1.11 - with left ventricular ejection fraction better than 35%, patients with an interval of more than 6 months had significantly higher risk of experiencing appropriate ICD therapy (log-rank P = 0.03). Covariate-adjusted hazard ratios for probability of appropriate ICD therapy associated with remote myocardial infarction were 1.09 (95% CI, 0.58 -2.04; P = 0.79) among patients with LVEF < 35%, and 2.68 (95% CI, 1.05 -6.86; P = 0.04) among those with LVEF > 35%.
Discussion
The benefit of ICD treatment has been well established among patients at high risk of sudden cardiac death in secondary and primary prevention settings. Several recent studies have examined risk factors for occurrence of appropriate ICD therapies. [7] [8] [9] [10] However, most studies included patients with various underlying cardiac conditions. There are few data providing long-term follow-up of ICD patients exclusively with coronary disease and without limitation of ejection fraction.
In the present study, we examined predictors of adequate ICD therapy in 245 patients with coronary disease who received an ICD for primary or secondary prevention of sudden cardiac death. We identified age and impaired left ven- tricular function as independent predictors of appropriate ICD therapy, whereas the extent of coronary disease was not predictive. Impaired renal function was also associated with a higher rate of appropriate ICD therapies, just reaching statistical significance in multivariate analysis. Among patients with left ventricular ejection fraction above 35%, a time interval of 6 months or more from myocardial infarction to implantation of an ICD was predictive of future therapies possibly due to progression of the disease.
Patients with left ventricular ejection fraction below 35% appear to benefit most from ICD therapy. 11, 12) Reduced left ventricular ejection fraction has been shown to increase the rate of ICD therapy delivery and mortality in several studies, 13, 14) but was not predictive in others. 15, 16) The time interval between myocardial infarction and device implantation may play an important role in determining which patients are at increased risk. Data from the MADIT II trial suggest that mortality risk in patients with ejection fraction 30% or lower increases as a function of time from myocardial infarction. 17) In the DINAMIT trial, which enrolled patients for ICD implantation within a few days after myocardial infarction, a reduction of arrhythmic deaths was offset by excess nonarrhythmic cardiac mortality. 4) In our study, however, time to implant was not associated with the risk of appropriate therapies among patients with left ventricular ejection fraction below 35%. In contrast, among patients with ejection fraction better than 35%, remote myocardial infarction was a significant predictor of future ICD therapies. Syncope or ventricular tachycardia occurring 6 months or later after myocardial infarction may therefore be associated with increased risk in patients without severe impairment of systolic left ventricular function. During an early phase after myocardial infarction, however, these symptoms seem to be associated with future arrhythmias primarily among patients with left ventricular ejection fraction below 35%. Although a majority of the patients who experienced ICD therapy did so within the first year following device implantation, some patients may remain free of ventricular arrhythmia for years (up to 12 years in our study) before receiving first adequate treatment. This fact is of paramount importance to consider at the point in time when patients present with battery depletion with the requirement of a device change.
In the current study, age was an independent predictor of appropriate ICD therapy. Advanced age may reflect multimorbidity and more advanced stage of cardiac disease, and may thus result in higher risk. However, this finding is in contrast to other studies, which did not find an association of age with increased risk of ICD therapy or mortality during shorter follow-up periods. 15, 18) Beta-blocking medication has been associated with reduced risk of adverse events in ICD treated patients with ischemic cardiomyopathy. 19, 20) Consequently, the overall rate of beta-blocker use was high among patients in the current study (88%). This high rate might explain the failure of our study to demonstrate a protective effect of beta-blockers.
Furthermore, we found that impaired renal function was independently associated with an increased rate of appropriate ICD therapies (P = 0.05). Although the mechanism of this association is unclear, this finding is in line with the results of previous studies, which have demonstrated a high incidence of appropriate ICD shocks and increased rate of arrhythmic deaths among ICD recipients with kidney disease. 21, 22) Proarrhythmia might be an important mechanism linking cardiovascular death and kidney disease, as the association of renal insufficiency with increased cardiovascular mortality may not fully be attributed to classical risk factors or endothelial dysfunction. 23) Limitations of the study: Due to the retrospective nature of this study, the accuracy of the data used depends on the accuracy of the electronic medical records and clinical charts. As in most studies assessing predictors of ICD therapies, clinical variables were considered at the point of ICD implantation, without accounting for changes over time during follow-up. Furthermore, as ventricular tachycardia occurs more frequently than sudden cardiac death, appropriate ICD therapies have not proven to be a valid surrogate of sudden cardiac death.
24)

Conclusion
Reduced left ventricular ejection fraction, advanced age, and renal impairment are long-term predictors of appropriate ICD therapy in patients with coronary disease at high risk of sudden cardiac death. Patients with an ejection fraction above 35% have few arrhythmic events early after the myocardial infarction, but appropriate therapies become more frequent late after the myocardial infarction, possibly due to progression of the disease.
